{"id":59061,"date":"2026-03-09T12:33:28","date_gmt":"2026-03-09T04:33:28","guid":{"rendered":"https:\/\/flcube.com\/?p=59061"},"modified":"2026-03-09T12:33:29","modified_gmt":"2026-03-09T04:33:29","slug":"bio-thera-wins-nmpa-approval-for-bat8008-bat1006-trastuzumab-combo-trial-dual-her2-trop2-targeting-in-advanced-solid-tumors","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=59061","title":{"rendered":"Bio-Thera Wins NMPA Approval for BAT8008 BAT1006 Trastuzumab Combo Trial \u2013 Dual HER2 Trop2 Targeting in Advanced Solid Tumors"},"content":{"rendered":"\n

Bio-Thera Solutions Ltd<\/strong> (SHA: 688177<\/a>) announced NMPA clearance<\/strong> to initiate a clinical study<\/strong> evaluating BAT8008<\/strong> (anti-Trop2 ADC) combined with BAT1006<\/strong> (anti-HER2 antibody) plus trastuzumab<\/strong> in HER2-positive advanced solid tumors<\/strong>. The triplet regimen represents a novel dual-HER2\/Trop2 targeting strategy<\/strong> leveraging Bio-Thera’s proprietary ADC platform and bispecific-like antibody engineering to address tumor heterogeneity in refractory cancers.<\/p>\n\n\n\n

Regulatory Milestone<\/h2>\n\n\n\n
Item<\/th>Detail<\/th><\/tr><\/thead>
Agency<\/strong><\/td>NMPA (China)<\/td><\/tr>
Approval Type<\/strong><\/td>Clinical trial authorization (IND)<\/td><\/tr>
Study Design<\/strong><\/td>BAT8008 + BAT1006 + trastuzumab combination<\/td><\/tr>
Indication<\/strong><\/td>HER2-positive advanced solid tumors<\/td><\/tr>
Developer<\/strong><\/td>Bio-Thera Solutions Ltd (SHA: 688177)<\/td><\/tr>
Approval Date<\/strong><\/td>March 2026<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Product Profiles & Mechanism<\/h2>\n\n\n\n

BAT8008 (Anti-Trop2 ADC)<\/h3>\n\n\n\n
Attribute<\/th>Specification<\/th><\/tr><\/thead>
Structure<\/strong><\/td>Recombinant humanized anti-Trop2 antibody + topoisomerase I inhibitor payload<\/td><\/tr>
Linker<\/strong><\/td>Self-developed cleavable linker<\/td><\/tr>
Mechanism<\/strong><\/td>Targeted delivery of cytotoxic payload to Trop2-expressing tumor cells<\/td><\/tr>
Key Feature<\/strong><\/td>Strong bystander effect<\/strong> \u2013 toxin diffusion kills neighboring antigen-negative cells, overcoming tumor heterogeneity<\/td><\/tr>
Activity<\/strong><\/td>Efficient anti-tumor activity in preclinical models<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

BAT1006 (Anti-HER2 Antibody)<\/h3>\n\n\n\n
Attribute<\/th>Specification<\/th><\/tr><\/thead>
Target<\/strong><\/td>HER2 extracellular dimerization domain (Subdomain II)<\/td><\/tr>
Mechanism<\/strong><\/td>Blocks ligand-dependent HER2 heterodimerization with EGFR, HER3, HER4<\/td><\/tr>
Downstream Effect<\/strong><\/td>Inhibition of MAP kinase and PI3K signaling pathways<\/td><\/tr>
Outcome<\/strong><\/td>Cell growth arrest and apoptosis<\/td><\/tr>
Differentiation<\/strong><\/td>Novel epitope targeting vs. trastuzumab (Subdomain IV)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Trastuzumab (Herceptin)<\/h3>\n\n\n\n

| Role | Established anti-HER2 backbone; Fc-mediated immune effector functions |<\/p>\n\n\n\n

Combination Rationale & Strategic Value<\/h2>\n\n\n\n
Component<\/th>Contribution to Triplet<\/th><\/tr><\/thead>
Trastuzumab<\/strong><\/td>HER2 signaling blockade (Subdomain IV) + ADCC-mediated tumor killing<\/td><\/tr>
BAT1006<\/strong><\/td>Complementary HER2 dimerization blockade (Subdomain II); broader HER family inhibition<\/td><\/tr>
BAT8008<\/strong><\/td>Trop2-directed cytotoxic payload; bystander effect addresses HER2-negative tumor clones<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Scientific Synergy:<\/strong><\/p>\n\n\n\n